OPTN OptiNose Corp: Enterprise Value to EBITDA Ratio
The business efficiency of OptiNose, Inc. (OPTN) relies on the sales of XHANCE nasal spray, which is supported by the market valuation reflected in the price chart with the indicator . OptiNose, Inc. (OPTN) is developing a precision drug delivery system for deep sinuses, establishing a new standard for ENT therapy. The current development vector is focused on aggressively increasing sales volumes of chronic sinusitis medications within the US region.
Comprehensive metric breakdowns and analytics for optinose.com (OPTN)
- market price and analyst price targets:
- company stock capitalization data:
- business book valuation details:
- debt obligations and liquidity statistics:
- financial results and valuation multiples details:
OPTN - Net Financial Result|Expected Profit OptiNose, Inc.|OPTN - Price to Earnings Multiple|Future Price to Earnings OptiNose, Inc.|OPTN - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization OptiNose Corp|OPTN - Operating income before deduction of amortization|Net earnings per share (EPS TTM) OptiNose|OPTN - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months optinose.com|OPTN - Earnings per share increase in current year|Earnings growth forecast for next year OptiNose, Inc.
Initial company analysis:OPTN (Optinose)
Stable sales of OptiNose, Inc. (OPTN) medical systems provide sufficient capital, making the company's EV/EBITDA chart a reliable tool for monitoring business value. This multiple compares the total enterprise value, including net debt, with operating profit before interest, taxes, depreciation, and amortization. A decline in this ratio may signal that the asset is undervalued or indicate rising credit risks, thereby determining the optimal entry point for an investor.
Direct competitors
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Haleon Group HLN|Kenvue Health (KVUE) - Company Value to EBITDA|VRNA: Enterprise Value to EBITDA Ratio|jyongbio.com - Enterprise Value to Operating Income Before Depreciation Ratio|LGND: EV/EBITDA Multiple|Amneal Pharmaceuticals, Inc. - Business Value to Operating Income Before Depreciation|PRGO (Perrigo Company) - EV/EBITDA Multiple|Company Value to EBITDA Alvotech Biopharmaceuticals ALVO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Liquidia Corporation (LQDA)|GLPG (glpg.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ANI Pharmaceuticals, Inc. ANIP|MannKind Corp (MNKD) - Company Value to EBITDA|AMPH - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio PCRX|SPRY (ARS Pharmaceuticals) - Enterprise Value to EBITDA Ratio|TBPH: Enterprise Value to Operating Income Before Depreciation Ratio|AQST (Aquestive Therapeutics, Inc.) - EV/EBITDA Multiple|scPharma (SCPH) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tectonic Therapeutic, Inc. (TECX)|Tonix Pharmaceuticals Holding - Enterprise Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization China SXT Pharmaceuticals, Inc. SXTC|Eupraxia Pharmaceuticals, Inc. (EPRX) - Company Value to EBITDA|BHST - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio Invizyne Technologies EXOZ|ORMP: EV/EBITDA Multiple|Company Value to EBITDA Entera Bio (ENTX)|Enterprise Value to EBITDA Ratio HYFT|ABVC: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple CPIX|Total Company Value to Operating Income Before Depreciation Ratio Quantum BioPharma Ltd.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization FibroGen Corp FGEN|TELO: Enterprise Value to Operating Income Before Depreciation|Rani Therapeutics Inc - EV/EBITDA Multiple|Synergy CHC Corp (SNYR) - Enterprise Value to EBITDA Ratio|RLYB (rallybio.com) - Enterprise Value to EBITDA Ratio|LEXX - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pulmatrix Corp|Company Value to EBITDA Pheton PTHL|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Aptorum Group Limited (APM)|LYRA: Company Value to Operating Income Before Depreciation Ratio|Impact BioMedical - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio TNFA (TNF Pharmaceuticals Inc.)|YCBD - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PRFX (PainReform Corp) - Enterprise Value to Operating Income Before Depreciation|altamiratherapeutics.com (CYTO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio LIPO (lipella.com)|PIRS (Pieris Pharmaceuticals, Inc.) - EV/EBITDA Multiple|PROC: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple PTPI|EV/EBITDA Multiple Qilian International Corp (QLI)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Acelyrin, Inc. SLRN|Business Value to Operating Income Before Depreciation TFFP
